Thu, Aug 21, 2014, 4:47 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Nxstage Medical, Inc. Message Board

biotuesday 2 posts  |  Last Activity: Jul 1, 2014 2:16 PM Member since: Oct 25, 2011
  • Leerink Partners has upgraded Amicus Therapeutics (NASDAQ:FOLD) to “outperform” from “market perform” and raised its price target to $6 from $2.50.......

  • Athersys (NASDAQ:ATHX) expects to complete enrollment by the end of the summer in a Phase 2 clinical trial of its MultiStem cell therapy in about 140 moderate to moderately-severe ischemic stroke patients, with data to be released before year end.

    “If we get the results we’re looking for, this could have a dramatic impact on stroke medicine and greatly improve treatment for more severe stroke patients,” chairman and CEO, Gil Van Bokkelen, says in an interview with BioTuesdays

    Cleveland-based Athersys is developing MultiStem for the treatment of conditions in the cardiovascular, neurological, inflammatory and immune disease areas.

    MultiStem is a biologic product manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources. The stem cell product can be expanded on a large scale for future use and stored in frozen form until needed....

    See BioTuesdays for rest of this week's feature article on ATHX

13.18+0.01(+0.08%)4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.